Free tool
Rare disease stocks
We cover 58 companies grouped under the Rare disease theme. The median market value in the group is $6.19B. Across the group, the median move over the past trading day is −0.04%. 76% of the 55 with a 200-day average trade above it. Price change over the past year runs from −13.9% to +206.7% across the middle 80 percent of the group, with a median of +57.8%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
58 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| VX1.DE | Vertex Pharmaceuticals Incorporated | 475.00 EUR | +10.21% | +23.55% | +41.64% |
| VRTX | Vertex Pharmaceuticals Incorporated | $547.29 | +11.60% | +21.05% | +40.66% |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | 204.00 EUR | −19.59% | −40.19% | −10.21% |
| ALNY | Alnylam Pharmaceuticals, Inc. | $239.00 | −17.13% | −40.28% | −47.38% |
| A1LN34.SA | Alnylam Pharmaceuticals, Inc. | 62.25 BRL | −15.31% | −44.14% | −49.35% |
| INSM | Insmed Incorporated | $124.39 | +19.46% | −29.77% | −7.54% |
| ROIV | Roivant Sciences Ltd. | $36.75 | +8.60% | +67.58% | +206.51% |
| JAZZ | Jazz Pharmaceuticals plc | $249.29 | −2.97% | +43.97% | +100.35% |
| ASND | Ascendis Pharma A/S | $250.25 | −1.65% | +17.33% | +29.66% |
| BBIO | BridgeBio Pharma, Inc. | $79.37 | −7.22% | +1.45% | +60.05% |
| CORT | Corcept Therapeutics Incorporated | $119.80 | +27.19% | +213.61% | +71.81% |
| 0JAV.L | Insmed Incorporated | $125.00 | +0.43% | −28.28% | −7.52% |
| BMRN | BioMarin Pharmaceutical Inc. | $65.61 | +5.70% | +10.36% | +11.85% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | 52.70 EUR | +2.53% | +10.68% | +1.80% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $89.12 | +3.89% | +31.46% | +308.99% |
| CYTK | Cytokinetics, Incorporated | $79.20 | −0.31% | +28.30% | +109.36% |
| IONS | Ionis Pharmaceuticals, Inc. | $63.36 | +14.58% | −20.47% | +48.21% |
| KYMR | Kymera Therapeutics, Inc. | $125.55 | +18.26% | +72.55% | +197.09% |
| 0JDI.L | Ionis Pharmaceuticals, Inc. | $63.37 | +3.44% | −19.72% | +47.26% |
| ABVX.PA | ABIVAX Société Anonyme | 102.30 EUR | −5.63% | −11.04% | +48.91% |
| PTGX | Protagonist Therapeutics, Inc. | $151.50 | +10.71% | +73.78% | +146.62% |
| IMVT | Immunovant, Inc. | $43.89 | +12.83% | +69.39% | +189.13% |
| 4151.T | Kyowa Kirin Co., Ltd. | 2,613.00 JPY | −3.33% | +3.94% | +4.01% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $111.87 | +3.54% | +6.53% | +9.35% |
| SRRK | Scholar Rock Holding Corporation | $60.04 | +21.61% | +40.28% | +74.18% |
| 0HI3.L | Arrowhead Pharmaceuticals, Inc. | $89.35 | +3.26% | +32.80% | +294.59% |
| ORKA | Oruka Therapeutics, Inc. | $99.44 | +9.94% | +251.75% | +555.07% |
| LQDA | Liquidia Corporation | $71.36 | −17.81% | +127.26% | +154.86% |
| TVTX | Travere Therapeutics, Inc. | $67.12 | +20.05% | +69.84% | +284.86% |
| DNTH | Dianthus Therapeutics, Inc. | $110.76 | +9.01% | +179.13% | +356.93% |
| PTCT | PTC Therapeutics, Inc. Common Stock | $72.69 | −3.58% | −5.28% | +46.02% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $78.68 | −0.96% | +87.31% | +133.47% |
| MIRM | Mirum Pharmaceuticals, Inc. | $98.51 | −12.22% | +26.18% | +31.96% |
| GRFS | Grifols, S.A. | $7.90 | −1.25% | −14.50% | −19.39% |
| DYN | Dyne Therapeutics, Inc. | $26.36 | +1.78% | +42.49% | +93.26% |
| EWTX | Edgewise Therapeutics, Inc. | $44.38 | +9.99% | +86.86% | +207.13% |
| MANE | Veradermics, Incorporated | $102.80 | −7.84% | +172.32% | +172.32% |
| CAMX.ST | Camurus AB (publ) | 615.00 SEK | −1.68% | +0.49% | −15.35% |
| CLDX | Celldex Therapeutics, Inc. | $40.57 | +14.02% | +50.20% | +79.51% |
| IRON | Disc Medicine, Inc. | $82.67 | +10.74% | +4.53% | +37.90% |
| ARQT | Arcutis Biotherapeutics, Inc. | $25.14 | −11.54% | −13.31% | +60.64% |
| 0RD1.L | Camurus AB (publ) | 609.98 SEK | −0.21% | −0.53% | −15.10% |
| VRDN | Viridian Therapeutics, Inc. | $24.26 | +24.35% | −20.93% | +30.71% |
| VERA | Vera Therapeutics, Inc. | $36.82 | +10.50% | −24.27% | +67.21% |
| RARE | Ultragenyx Pharmaceutical Inc. | $26.44 | +1.77% | +12.03% | −12.10% |
| PHVS | Pharvaris N.V. | $37.00 | +9.97% | +39.73% | +55.59% |
| TRVI | Trevi Therapeutics, Inc. | $17.92 | −2.77% | +50.71% | +124.00% |
| NKTR | Nektar Therapeutics | $73.77 | +4.24% | +69.90% | +151.95% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $9.83 | +0.92% | +31.07% | +15.38% |
| 009420.KS | Hanall Biopharma Co., Ltd. | 64,000.00 KRW | +53.48% | +51.66% | +112.62% |
| COAG | Hemab Therapeutics Holdings, Inc. | $49.19 | +4.08% | +44.68% | +44.68% |
| MLYS | Mineralys Therapeutics, Inc. | $25.89 | −3.93% | −27.50% | +70.22% |
| PVLA | Palvella Therapeutics, Inc. | $154.33 | +8.04% | +53.90% | +173.39% |
| AUPH | Aurinia Pharmaceuticals Inc. | $16.54 | +10.56% | +7.75% | +36.58% |
| ADMA | ADMA Biologics, Inc. | $9.63 | +9.56% | −46.14% | −44.17% |
| ZBIO | Zenas BioPharma, Inc. | $33.04 | +2.32% | −4.23% | +97.73% |
| STOK | Stoke Therapeutics, Inc. | $33.09 | +12.59% | +7.09% | +71.45% |
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | $33.99 | −5.56% | +25.06% | −13.45% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.